Sign up
Pharma Capital

Motif Bio teams up with German university to see if iclaprim can help patients with rare eye disease

Researchers at the Otto-von-Guericke University Magdeburg are to carry out a series of lab tests to evaluate iclaprim as a possible treatment for toxoplasma chorioretinitis
An orphan disease is a condition that affects fewer than 200,000 people around the world

Motif Bio PLC (LON:MTFB) is to explore the possibility of using its iclaprim next-generation antibiotic to treat people with a rare blindness-causing disease called toxoplasma chorioretinitis.

AIM-quoted Motif has tested iclparim in patients with acute bacterial skin and skin structure infections (ABSSSI), for which it is now looking to get regulatory approval.

READ: Motif bosses meet with FDA

But the company has today signed an agreement with the Otto-von-Guericke University Magdeburg in Germany which is to carry out a series of lab tests to see if iclaprim can help people affected by toxoplasma chorioretinitis.

The orphan disease that is a type of ocular toxoplasmosis – a parasitic disease that may result in severe life-threatening infections and/or blindness.

The work will be carried out by professor Ildiko Rita Dunay, a director at the university’s Institute of Inflammation and Neurodegeneration.

“We are very pleased to work with Dr Dunay, who is an expert in the area of toxoplasmosis. In vitro data indicate that iclaprim has activity against toxoplasma,” said chief medical officer David Huang.

“The data generated from Dr Dunay's lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications.”

View full MTFB profile View Profile

Motif Bio meets FDA

View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.